Dana Farber PLGA
  • Home
  • About
  • Team
  • Research
  • Publications
  • News
  • Contact
  • Support
  • Search
  • Menu Menu

Publications

2019

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
Neuro Oncology. Feb 2019/21(8):968-980.

The power of human cancer genetics as revealed by low-grade gliomas.
Annual Review of Genetics. Dec 2019/53;483-503.

Old meet new-the path to combination treatments in pediatric low-grade gliomas.
Neuro Oncology. Feb 2019/21(2);143-145.

Mitogenic and progenitor gene programs in single pilocytic astrocytoma cells.
Nature Communications. August 2019/ 10(1):3731.

Management of pediatric low-grade glioma.
Current Opinions in Pediatrics. Feb 2019/31 (1);21-27.

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
Nature. 2019 Nov/575(7783);545-550.
2018

Rapid discrimination of pediatric brain tumors by mass spectrometry imaging.
Journal of Neuro-Oncology. 2018 Nov; 140(2):269-279.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Cell Chem Biol. 2018 Jan; 25(1):88-99.

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.
J Neurooncology. April 2018/137(2):269-278..
2017

Brainstem angiocentric gliomas with MYB-QKI rearrangements.
Acta Neuropathology. 2017; 134(4):667-669.

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
Neuro Oncol. 2017 Jun; 19(6):774-785.
2016

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.
Nature Genetics. 2016 Mar;48(3):273-82.

A Landscape of Pharmacogenomic Interactions in Cancer
Cell. 2016 Jul; 166(3):740-754.
2015

Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
Pediatr Blood Cancer. 2015 Jan;62(1):3-4.
2014

Diffuse intrinsic pontine glioma: a reassessment
J Neurooncol. 2014 Aug;119(1):7-15.

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
Pediatr Blood Cancer. 2014 61(4):636-42.

Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database.
Pediatr Blood Cancer. 2014 Jan 30.

An amino terminal phosphorylation motif regulates intranuclear compartmentalization of Olig2 in neural progenitor cells
J. Neuroscience. 2014 Jun; 34(25):8507-18.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF and NRAS mutant malignancies
Cancer Discov. 2014 Mar 3.

Pediatric low-grade gliomas: How modern biology reshapes the clinical field
Biochem Biophys Acta. 2014 1845(2) 294-307.

Genome sequencing of SHH medulloblastoma predicts genoType-related response to smoothened inhibition
Cancer Cell. 2014 Mar 17;25(3):393-405.

Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling
Sci Transl Med. 2012 4(148) 148ra117.

Phase II trial of pirfenidone in children and young adults with neurofibromatosis Type 1 and progressive plexiform neurofibromas
Pediatr Blood Cancer. 2014 Sep;61(9):1598-602.

Distinct BimBH3 (BimSAHB) Stapled Peptides for Structural and Cellular Studies
ACS Chem Biol. 2014 9(3):831-7.

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy
J Clin Oncol. 2014 Aug 4. pii: JCO.2013.51.1766.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Neuro Oncol. 2014 May:16 (%):707-18.

Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging
J Neurosurg Pediatr. Oct;14(4):356-64..

Targeting BRAF in pediatric brain tumors
Am Soc Clin Oncol Educ Book. 2014:e436-40.

Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
Proc Natl Acad Sci USA. 2014 Jul: 111(30):11121-6.

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Nat Genet. 2014 Feb;46(2):161-5.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
PNAS. 2014 Nov 11;111(45):E4869-77.
2013

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities
Nat Med. 2013 Nov 19(11):1518-23.

Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1611-6.

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
International Cancer Genome Consortium PedBrain Tumor Project. Nat Genet. 2013 Aug;45(8):927-32. doi: 10.1038/ng.2682. Epub 2013 Jun 30. PMID:23817572.

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
Nat Genet. 2013 Aug: 45(8):927-32.

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
Proc Natl Acad Sci USA. 2013 May 14;110(20):8188-93. PMID:23633565.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
Cancer Res. 2013 Apr 15;73(8):2574-86.

Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state
Science. 2013 Jul 19; 341(6143). PMID:1238303.

Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
Nat Biotechnol. 2013 Jul; 31(7):630-7. PMID:23811600.

Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging
Sci Rep. 2013 Oct 4;3:2859. .

Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy
Sci Transl Med. 2013 Sep 4;5(201):201ra119.

PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma
Brain Pathol. 2013 Sep;23(5):565-73. doi: 10.1111/bpa.12043. Epub 2013 Mar 18. PMID:23438035.
2012

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
Blood Cancer. 2012 Dec 15;59(7):1155-7. doi: 10.1002/pbc.24315. Epub 2012 Sep 19. PMID:2997201.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
Cancer Cell. 2012 Nov 13;22(5):668-82.

Systematic identification of genomic markers of drug sensitivity in cancer cells
Nature. 2012 Mar 28;483(7391):570-5.

Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2
Nat Rev Neurosci. 2012 Dec;13(12):819-31. PMID:23165259.
2011

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma
Cancer Cell. 2011 Mar 8;19(3):359-71.

Phosphorylation state of Olig2 regulates proliferation of neural progenitors
Neuron. 2011 Mar 10;69(5):906-17.
DF PLAG logo
New Patient Coordinator
PLGA Fund
DF PLAG Harvard logo
© 2020 Dana Farber PLGA. All rights reserved. Site by Academic Web Pages.
Scroll to top